AAAAAA

   
Results: 1-13 |
Results: 13
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees
Authors: Newman, R Hariharan, K Reff, M Anderson, DR Braslawsky, G Santoro, D Hanna, N Bugelski, PJ Brigham-Burke, M Crysler, C Gagnon, RC Dal Monte, P Doyle, ML Hensley, PC Reddy, MP Sweet, RW Truneh, A
Citation: R. Newman et al., Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees, CLIN IMMUNO, 98(2), 2001, pp. 164-174
Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat
Authors: Toseland, CDN Campbell, S Francis, I Bugelski, PJ Mehdi, N
Citation: Cdn. Toseland et al., Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat, DIABET OB M, 3(3), 2001, pp. 163-170
Maximization of signal derived from cDNA microarrays
Authors: Wildsmith, SE Archer, GE Winkley, AJ Lane, PW Bugelski, PJ
Citation: Se. Wildsmith et al., Maximization of signal derived from cDNA microarrays, BIOTECHNIQU, 30(1), 2001, pp. 202
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
Authors: Hart, TK Cook, RM Zia-Amirhosseini, P Minthorn, E Sellers, TS Maleeff, BE Eustis, S Schwartz, LW Tsui, P Appelbaum, ER Martin, EC Bugelski, PJ Herzyk, DJ
Citation: Tk. Hart et al., Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys, J ALLERG CL, 108(2), 2001, pp. 250-257
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice
Authors: Herzyk, DJ Gore, ER Polsky, R Nadwodny, KL Maier, CC Liu, S Hart, TK Harmsen, AG Bugelski, PJ
Citation: Dj. Herzyk et al., Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice, INFEC IMMUN, 69(2), 2001, pp. 1032-1043
Chemometric strategies for normalisation of gene expression data obtained from cDNA microarrays
Authors: Wu, W Wildsmith, SE Winkley, AJ Yallop, R Elcock, FJ Bugelski, PJ
Citation: W. Wu et al., Chemometric strategies for normalisation of gene expression data obtained from cDNA microarrays, ANALYT CHIM, 446(1-2), 2001, pp. 451-466
Nonlinear dynamics in the progression of atherosclerotic fatty streaks: Morphometric analysis
Authors: Bugelski, PJ Maleeff, BE Klinkner, AM Louden, CS Hart, TK
Citation: Pj. Bugelski et al., Nonlinear dynamics in the progression of atherosclerotic fatty streaks: Morphometric analysis, MICROS MICR, 6(6), 2000, pp. 532-541
Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system
Authors: O'Brien, PJ Slaughter, MR Swain, A Birmingham, JM Greenhill, RW Elcock, F Bugelski, PJ
Citation: Pj. O'Brien et al., Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system, HUM EXP TOX, 19(5), 2000, pp. 277-283
Preclinical development of keliximab, a Primatized (TM) anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model andsafety studies
Authors: Bugelski, PJ Herzyk, DJ Rehm, S Harmsen, AG Gore, EV Williams, DM Maleeff, BE Badger, AM Truneh, A O'Brien, SR Macia, RA Wier, PJ Morgan, DG Hart, TK
Citation: Pj. Bugelski et al., Preclinical development of keliximab, a Primatized (TM) anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model andsafety studies, HUM EXP TOX, 19(4), 2000, pp. 230-243
A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology
Authors: Bugelski, PJ Atif, U Molton, S Toeg, I Lord, PG Morgan, DG
Citation: Pj. Bugelski et al., A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology, PHARM RES, 17(10), 2000, pp. 1265-1272
Evaluation of Alamar Blue reduction for the in vitro assay of hepatocyte toxicity
Authors: Slaughter, MR Bugelski, PJ O'Brien, PJ
Citation: Mr. Slaughter et al., Evaluation of Alamar Blue reduction for the in vitro assay of hepatocyte toxicity, TOX VITRO, 13(4-5), 1999, pp. 567-569
Atiprimod (SK & F106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice
Authors: Badger, AM Handler, JA Genell, CA Herzyk, D Gore, E Polsky, R Webb, L Bugelski, PJ
Citation: Am. Badger et al., Atiprimod (SK & F106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice, INT J IMMUN, 21(3), 1999, pp. 161-176
Selective inhibition of phospholipases by atiprimod, a macrophage targeting antiarthritic compound
Authors: Handler, JA Badger, A Genell, CA Klinkner, AM Kassis, S Waites, CR Bugelski, PJ
Citation: Ja. Handler et al., Selective inhibition of phospholipases by atiprimod, a macrophage targeting antiarthritic compound, TOX APPL PH, 159(1), 1999, pp. 9-17
Risultati: 1-13 |